<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355585</url>
  </required_header>
  <id_info>
    <org_study_id>2020P000440</org_study_id>
    <nct_id>NCT04355585</nct_id>
  </id_info>
  <brief_title>Revisiting the Mechanism of the Anti-inflammatory Effect of Colchicine</brief_title>
  <official_title>Revisiting the Mechanism of the Anti-inflammatory Effect of Colchicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard Medical School (HMS and HSDM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are doing this research study to better understand the mechanism of action of colchicine,&#xD;
      a drug commonly prescribed for gout. Precisely, we aim to evaluate the effect of colchicine&#xD;
      on a specific protein (GDF15) blood levels at different timepoints after its administration.&#xD;
&#xD;
      This research study will compare GDF15 blood levels after the administration of colchicine or&#xD;
      placebo. The placebo looks exactly like colchicine but contains no active drug. During this&#xD;
      study, participants may get a placebo instead of colchicine. Placebos are used in research&#xD;
      studies to see if the results are due to the study drug or due to other reasons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, placebo-controlled, double-blind, pilot study evaluating the&#xD;
      effect of a single FDA-approved dose of colchicine in healthy adults on plasma GDF15 levels.&#xD;
      Randomization will be stratified by sex as this may be a factor influencing GDF15 levels.&#xD;
&#xD;
      On Day 1, subjects will be admitted on the CCI 9A unit early in the morning, 30 minutes&#xD;
      before the study drug administration. They will be asked to fast from midnight before the&#xD;
      dose until 2 hours after. Water is allowed during the fasting period. Baseline blood tests&#xD;
      will be drawn and a peripheral line will be left in place for further blood draws. A dose of&#xD;
      either colchicine or placebo will be administered. Blood samples will be drawn at 2, 4, 6, 8,&#xD;
      10 and 12 hours. The patient will be discharged home after the last blood draw and the&#xD;
      removal of the peripheral line. Two other blood draws will be performed using standard&#xD;
      procedures at 24 and 48 hours post study drug administration at the research clinic&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 6, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Stratified randomization according to sex will be performed. Each group will be randomized to receive colchicine or placebo.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a double-blind study in which investigators, participants, site personnel, and laboratory staff will be blinded during the study. Only the research pharmacy will have access to randomization and treatment assignments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma GDF15 levels</measure>
    <time_frame>Before product administration and 2, 4, 6 ,8, 10,12, 24 and 48 hours after product administration</time_frame>
    <description>The primary endpoint will be the plasma GDF15 level before and at different timepoints after colchicine administration. Plasma GDF-15 level will be determined using an enzyme immunoassay (EIA) testing.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Colchicine Mechanism of Action</condition>
  <arm_group>
    <arm_group_label>Male</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Female</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will be randomized to receive either a single dose of colchicine (1.8mg administered over 1 hour in the form of tablets) or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine Tablets</intervention_name>
    <description>1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)</description>
    <arm_group_label>Female</arm_group_label>
    <arm_group_label>Male</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo given over 1 hour (first tablet followed by second tablet 1 hour later)</description>
    <arm_group_label>Female</arm_group_label>
    <arm_group_label>Male</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant able to understand and sign the informed consent of the study&#xD;
&#xD;
          -  Healthy male or female aged from 18 to 50 years.&#xD;
&#xD;
          -  Participant considered healthy after evaluation such as medical history and screening&#xD;
             laboratories.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Use of colchicine within 28 days prior to study drug administration.&#xD;
&#xD;
          -  Renal insufficiency (GFR &lt; 50 mL/min)&#xD;
&#xD;
          -  Use of any drug or product known to interact with colchicine including CYP3A4 and/or&#xD;
             P-glycoprotein (P-gp) inhibitors in the 14 days prior study drug administration, such&#xD;
             as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone,&#xD;
             nelfinavir, ritonavir, saquinavir, telithromycin, amprenavir, aprepitant, diltiazem,&#xD;
             erythromycin, fluconazole, fosamprenavir, verapamil, cyclosporine and ranolazine.&#xD;
             Significant consumption of grapefruit juice can also inhibit CYP3A4. Interactions may&#xD;
             also be seen with fibrates (e.g., gemfibrozil), HMG-CoA reductase inhibitors (statins)&#xD;
             and digoxin.&#xD;
&#xD;
          -  History of colchicine allergy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Baden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindsey Baden, MD</last_name>
    <phone>978-VACCINE</phone>
    <email>vaccines@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Cauley</last_name>
    <phone>6177325394</phone>
    <email>jcauley@bwh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 18, 2020</study_first_submitted>
  <study_first_submitted_qc>April 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Lindsey R. Baden, MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>pharmacology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified data will be made available upon request to the principal investigator following the publication of the primary manuscript.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

